Ionis Pharmaceuticals (NASDAQ: IONS) in Carlsbad pioneered antisense oligonucleotide technology from its Gazelle Court headquarters in the 92010 biotech corridor, building the RNA-targeted drug discovery platform that produced the first approved treatment for spinal muscular atrophy. Founded in 1989, the company employs approximately 1,069 scientists and staff, advancing antisense medicines for neurological, cardiovascular, and rare diseases — research that ultimately reaches patients through community health infrastructure represented by TrueCare Carlsbad on the delivery end of the clinical pipeline. Spinraza (nusinersen), the first and only FDA-approved therapy for all patients with spinal muscular atrophy, and Tegsedi (inotersen), the first RNA-targeted drug approved for hereditary transthyretin amyloidosis polyneuropathy, both originated from the Carlsbad antisense platform. The proprietary drug discovery engine has produced multiple FDA-approved medicines and over 50 clinical-stage candidates, anchoring Carlsbad's RNA therapeutics corridor where Claragene and other gene-therapy companies advance complementary modalities. Antisense oligonucleotides designed at the Carlsbad campus bind specific mRNA sequences to degrade toxic proteins or correct aberrant gene splicing, enabling precision targeting across more than 30 active neurological and cardiometabolic development programs.